Condition (MeSH)
Histoplasmosis
ClinicalTrials.gov lists 26 trials for Histoplasmosis or a narrower condition beneath it. National Institute of Allergy and Infectious Diseases (NIAID) has the most among industry and government lead sponsors, with 5.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
26 of the 26 trials are tagged with Histoplasmosis itself; the rest are tagged with a narrower condition beneath it.
When did Histoplasmosis trials start? (12)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Not applicable
- Observational
Top of scale: 2
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 3 |
| 2025 | 1 |
| 2020 | 1 |
| 2018 | 1 |
| 2017 | 2 |
| 2015 | 1 |
| 2013 | 2 |
| 2009 | 1 |
| 2008 | 1 |
| 2007 | 2 |
Showing 10 of 12 earlier years.
No forecast is made for this condition: it averages 0.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 26 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Histoplasmosis trials in? (7)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 2 |
| Phase 1/2 | 3 |
| Phase 2 | 5 |
| Phase 2/3 | 1 |
| Phase 3 | 7 |
| Not applicable | 3 |
| Observational | 5 |
How many Histoplasmosis trials are recruiting? (5)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 3 |
| Recruiting | 1 |
| Completed | 17 |
| Withdrawn | 1 |
| Unknown status | 4 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Histoplasmosis trials? (7)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | 5 |
| Janssen, LP | 2 |
| National Center for Research Resources (NCRR) | 2 |
| National Eye Institute (NEI) | 2 |
| ANRS, Emerging Infectious Diseases | 1 |
Showing 5 of 7 sponsors.
Which drugs are being tested for Histoplasmosis? (1)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Itraconazole | 7 |
Interventions as named in the registry (14)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Fluconazol | 2 |
| ranibizumab PRN | 2 |
| 2 doses of L-AmB | 1 |
| single dose of L-AmB | 1 |
| 2.0 aflibercept | 1 |
Showing 5 of 14 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Histoplasmosis trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| KDIGO | 11 | 1 |
| Acute kidney injury | 7 | 1 |
| Diarrhoea | 6 | 1 |
| Pneumonia | 6 | 3 |
| Respiratory failure | 6 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Histoplasmosis? (34)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Single High Dose of Liposomal Amphotericin B in Human Immunodeficiency Virus/AIDS-Related Disseminated Histoplasmosis: A Randomized Trial. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 2023 | Yes |
| Bone Marrow Culture Yield for the Diagnosis of Opportunistic Diseases in Patients with AIDS and Disseminated Kaposi Sarcoma. | Current HIV research | 2020 | Yes |
| The occurrence of histoplasmosis in Brazil: A systematic review. | International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases | 2019 | Yes |
| Ranibizumab versus photodynamic therapy for presumed ocular histoplasmosis syndrome. | Ophthalmic surgery, lasers & imaging retina | 2013 | Yes |
| Investigation of the cause of death in a gene-therapy trial. | The New England journal of medicine | 2009 | Yes |
Showing 5 of 34 publications.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Histoplasmosis | 390 | Exact | Orphadata Science knowledge files, Product 1 |
| Histoplasmosis | 390 | Exact | Orphanet Rare Disease Ontology (ORDO) |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and sub-conditions in mesh.